Final results of the Offer for Kiadis: 97.39% of Kiadis Shares in
total committed under the Offer
This is a joint press release by Sanofi Foreign
Participations B.V. (the “Offeror”), Sanofi
(“Sanofi”) and Kiadis Pharma N.V.
(“Kiadis”), pursuant to the provisions of Article
17 paragraph 4 of the Netherlands Decree in Public Takeover Bids
(Besluit openbare biedingen Wft, the “Decree”) in
connection with the recommended public offer by the Offeror for all
the issued and outstanding ordinary shares in the capital of Kiadis
(the “Offer”). This announcement does not
constitute an offer, or any solicitation of any offer, to buy or
subscribe for any securities. Any offer will be made only by means
of the offer memorandum dated 10 February 2021 (the
“Offer Memorandum”), approved by
the Dutch Authority for the Financial Markets (Autoriteit
Financiële Markten, the “AFM”) on 10 February 2021
and recognized by the Belgian Authority for the Financial Markets
(Autoriteit voor Financiële Diensten en Markten) on 11 February
2021. This announcement is not for release, publication or
distribution, in whole or in part, in or into, directly or
indirectly, any jurisdiction in which such release, publication or
distribution would be unlawful. Terms not defined in this press
release will have the meaning as set forth in the Offer
Memorandum.
Final results of the Offer for
Kiadis: 97.39% of
Kiadis Shares in total
committed under the Offer
- During the Post-Closing Acceptance
Period, approximately 2.35% of the Shares on a Fully Diluted basis
were tendered under the Offer.
- Including Shares already held by
Sanofi following Settlement, this represents a total of 97.39% of
the Shares on a Fully Diluted basis.
- Settlement of Shares tendered
during the Post-Closing Acceptance Period will take place on 3 May
2021.
- Sanofi will initiate statutory
Buy-Out proceedings in an expeditious manner in order to obtain
100% of the Shares.
- The last trading date of the Shares
on Euronext Amsterdam and Euronext Brussels
("Euronext") will be 24 May 2021 and listing and
trading of the Shares will terminate as of 25 May 2021.
Paris, France and Amsterdam,
The Netherlands, 29
April 2021 – The Offeror, Sanofi
(Euronext: SAN and NYSE: SNY) and Kiadis (Euronext Amsterdam and
Brussels: KDS) today are pleased to announce that during
the Post-Closing Acceptance Period, which expired at 17:40 (CET)
today, 1,436,922 Shares were tendered under the Offer, representing
approximately 2.35% of the aggregate issued and outstanding
ordinary share capital of Kiadis on a Fully Diluted basis.
Including the 58,051,156 Shares already held by Sanofi following
Settlement, this is a total of 59,488,078 Shares, representing
approximately 97.39% of the aggregate issued and ordinary
outstanding share capital of Kiadis on a Fully Diluted basis.
SettlementShareholders who
accepted the Offer shall receive the Offer Price for each Tendered
Share tendered during the Post-Closing Acceptance Period and
transferred (geleverd) to the Offeror for acceptance pursuant to
the Offer, under the terms and conditions set out in the Offer
Memorandum. Reference is made to Section 5.12 (Post-Closing
Acceptance Period) of the Offer Memorandum.
Settlement of the Shares and payment of the
Offer Price will take place on 3 May 2021. Following settlement of
the Shares tendered during the Post-Closing Acceptance Period, the
Offeror will (directly or indirectly) hold 59,488,078 Shares,
representing approximately 97.39% of the aggregate issued and
outstanding ordinary share capital of Kiadis on a Fully Diluted
basis.
ING Bank N.V. has been acting as settlement and
exchange agent in connection with the Offer.
Buy-OutSince the Offeror owns
more than 95% of the Shares, the Offeror will initiate the
statutory Buy-Out in an expeditious manner in order to obtain 100%
of the Shares. Reference is made to section 6.11(c) (Buy-Out) of
the Offer Memorandum.
Delisting As a result of the
acquisition of more than 95% of the Shares by the Offeror, the
listing and trading of the Shares on Euronext will be
terminated.
In consultation with Euronext, it has been
decided that the last day of trading of the Shares will be on 24
May 2021. This means that the termination of the listing of the
Shares shall be effective as of 25 May 2021. Reference is made to
Sections 6.11(a) (Intentions following the Offer being declared
unconditional) and Section 6.11(b) (Liquidity and delisting) of the
Offer Memorandum.
Dutch Translation/ Nederlandse
vertaling
- Tijdens de Na-aanmeldingstermijn is
ongeveer 2.35% van de Aandelen op basis van Volledige Verwatering
aangemeld onder het Bod.
- Inclusief de Aandelen die na
Overdracht reeds door Sanofi worden gehouden, vertegenwoordigt dit
een totaal van 97.39% van de Aandelen op basis van Volledige
Verwatering.
- Overdracht van de Aandelen die zijn
aangemeld tijdens de Na-aanmeldingstermijn vindt plaats op 3 mei
2021.
- Sanofi zal op korte termijn de
wettelijke Uitkoopprocedure initiëren om 100% van de Aandelen te
verkrijgen.
- De laatste handelsdag van de
Aandelen aan Euronext Amsterdam en Euronext Brussel
("Euronext") zal op 24 mei 2021 zijn en de
notering van en de handel in de Aandelen zal eindigen per 25 mei
2021.
Parijs, Frankrijk en Amsterdam,
Nederland, 29 april 2021 – De
Bieder, Sanofi (Euronext: SAN en NYSE: SNY) en Kiadis (Euronext
Amsterdam en Brussel: KDS) zijn verheugd vandaag aan te
kondigen dat tijdens de Na-aanmeldingstermijn, die vandaag om 17:40
(CET) is geëindigd, 1,436,922 Aandelen zijn aangemeld onder het
Bod, wat ongeveer 2.35% van het geplaatst en uitstaand gewoon
aandelenkapitaal van Kiadis op basis van Volledige Verwatering
vertegenwoordigt. Inclusief de 58,051,156 Aandelen die na
Overdracht reeds door Sanofi worden gehouden, zijn dit in totaal
59,488,078 Aandelen, wat ongeveer 97.39% van het geplaatst en
uitstaand gewoon aandelenkapitaal van Kiadis op basis van Volledige
Verwatering vertegenwoordigt.
OverdrachtAandeelhouders die
het Bod hebben geaccepteerd zullen de Biedprijs ontvangen voor elk
tijdens de Na-aanmeldingstermijn Aangemeld Aandeel dat aan de
Bieder is geleverd, onder de voorwaarden zoals uiteengezet in het
Biedingsbericht. Verwezen wordt naar Hoofdstuk 5.12 (Post-Closing
Acceptance Period) van het Biedingsbericht.
Overdracht van de Aandelen en betaling van de
Biedprijs zal plaatsvinden op 3 mei 2021. Na overdracht van de
Aandelen die zijn aangemeld tijdens de Na-aanmeldingstermijn zal de
Bieder (direct of indirect) 59,488,078 Aandelen bezitten, wat
ongeveer 97.39% van het totaal geplaatst en uitstaand gewoon
aandelenkapitaal van Kiadis op basis van Volledige Verwatering
vertegenwoordigt.
ING Bank N.V. heeft opgetreden als omwissel- en
betaalkantoor in verband met het Bod.
UitkoopprocedureAangezien de
Bieder meer dan 95% van de Aandelen houdt, zal de Bieder spoedig de
wettelijke Uitkoopprocedure in gang zetten om 100% van de Aandelen
te verkrijgen. Verwezen wordt naar Hoofdstuk 6.11(c) (Buy-Out) van
het Biedingsbericht.
Beëindiging van de
beursnoteringAls gevolg van de
verkrijging van meer dan 95% van de Aandelen door de Bieder, zal de
notering van en de handel in de Aandelen aan Euronext worden
beëindigd.
In samenspraak met Euronext is besloten dat de
laatste handelsdag van de Aandelen 24 mei 2021 zal zijn. Dit
betekent dat de beëindiging van de notering van de Aandelen van
kracht wordt per 25 mei 2021. Verwezen wordt naar Hoofdstuk 6.11(a)
(Intentions following the Offer being declared unconditional) en
Hoofdstuk 6.11(b) (Liquidity and delisting) van het
Biedingsbericht.
Dit is een vertaling van het
oorspronkelijke in de Engelse taal opgestelde persbericht en deze
vertaling wordt uitsluitend voor informatieve doeleinden verstrekt.
In geval van verschillen tussen beide versies prevaleert de Engelse
tekst. Aan de vertaling kunnen geen rechten worden
ontleend.
AnnouncementsAny announcement
contemplated by the Offer Memorandum will be issued by press
release. Any press release issued by the Offeror will be made
available on the website of the Offeror (www.sanofi.com). Any press
release issued by Kiadis will be made available on the website
(www.kiadis.com).
Subject to any applicable requirements of the
applicable rules and without limiting the manner in which the
Offeror may choose to make any public announcement, the Offeror
will have no obligation to communicate any public announcement
other than as described above.Offer Memorandum, Position
Statement and further informationThis announcement
contains selected, condensed information regarding the Offer and
does not replace the Offer Memorandum and/or the Position
Statement. The information in this announcement is not complete and
additional information is contained in the Offer Memorandum and the
Position Statement.
Digital copies of the Offer Memorandum are
available on the website of the Offeror (www.sanofi.com) and
digital copies of the Position Statement are available on the
website of Kiadis (www.kiadis.com). Such websites do not constitute
part of, and are not incorporated by reference into, the Offer
Memorandum. Copies of the Offer Memorandum and the Position
Statement are on request also available free of charge at the
offices of Kiadis and the Settlement Agent at the addresses
below:
Kiadis Kiadis Pharma N.V.Paasheuvelweg 25A1105 BP AmsterdamThe
Netherlands |
Settlement AgentING Bank N.V.Bijlmerdreef 106 1102 CT Amsterdam The
Netherlands |
For more information:
Kiadis:Maryann
Cimino, Sr. Manager, Corporate AffairsTel: +1 (617) 710
7305m.cimino@kiadis.comKiadis Media Relations
ContactsLifeSpring Life Sciences
Communication:Leon Melens (Amsterdam)Tel: +31 (20) 538 16
427lmelens@lifespring.nlOptimum Strategic
Communications:Mary Clark, Supriya MathurTel: +44 (203)
950 9144kiadis@optimumcomms.com |
Sanofi:Sanofi Media
Relations ContactAshleigh KossTel.: +1 (908) 205
2572ashleigh.koss@sanofi.comSanofi Investor Relations
Contacts ParisEva Schaefer-JansenArnaud DelepineYvonne
NaughtonSanofi Investor
Relations Contacts North AmericaFelix LauscherFara
BerkowitzSuzanne GrecoIR main line:Tel.: +33 (1) 53 77 45
45ir@sanofi.com |
About Kiadis Founded in 1997,
Kiadis is committed to developing innovative cell-based medicines
for patients with life-threatening diseases. With headquarters in
Amsterdam, The Netherlands, and offices and activities across the
United States, Kiadis is reimagining medicine by leveraging the
natural strengths of humanity and our collective immune system to
source the best cells for life.
Kiadis is listed on the regulated market of
Euronext Amsterdam and Euronext Brussels since July 2, 2015, under
the symbol KDS. Learn more at www.kiadis.com.
About SanofiSanofi is dedicated
to supporting people through their health challenges. It is a
global biopharmaceutical company focused on human health. Sanofi
prevents illness with vaccines and provides innovative treatments
to fight pain and ease suffering. Sanofi stands by the few who
suffer from rare diseases and the millions with long-term chronic
conditions.
With more than 100,000 people in 100 countries,
Sanofi is transforming scientific innovation into healthcare
solutions around the globe.
Sanofi, Empowering Life.
DisclaimerThis press release
contains inside information within the meaning of the EU Market
Abuse Regulation (596/2014).
The information in the press release is not
intended to be complete. This announcement is for information
purposes only and does not constitute an offer, or any solicitation
of any offer, to buy or subscribe for any securities.
The distribution of this press release may, in
some countries, be restricted by law or regulation. Accordingly,
persons who come into possession of this document should inform
themselves of and observe these restrictions. To the fullest extent
permitted by applicable law, Sanofi and Kiadis disclaim any
responsibility or liability for the violation of any such
restrictions by any person. Any failure to comply with these
restrictions may constitute a violation of the securities laws of
that jurisdiction. Neither Sanofi, nor Kiadis, nor any of their
advisors assumes any responsibility for any violation by any of
these restrictions. Any Kiadis shareholder who is in any doubt as
to his or her position should consult an appropriate professional
advisor without delay.
Kiadis
forward-looking
statementsCertain statements,
beliefs and opinions in this press release are forward-looking,
which reflect Kiadis’ or, as appropriate, Kiadis’ officers’ current
expectations and projections about future events. By their nature,
forward-looking statements involve a number of known and unknown
risks, uncertainties and assumptions that could cause actual
results, performance, achievements or events to differ materially
from those expressed, anticipated or implied by the forward-looking
statements. These risks, uncertainties and assumptions could
adversely affect the outcome and financial effects of the plans and
events described herein. A multitude of factors including, but not
limited to, changes in demand, regulation, competition and
technology, can cause actual events, performance, achievements or
results to differ significantly from any anticipated or implied
development. Forward-looking statements contained in this press
release regarding past trends or activities should not be taken as
a representation that such trends or activities will continue in
the future. As a result, Kiadis expressly disclaims any obligation
or undertaking to release any update or revisions to any
forward-looking statements in this press release as a result of any
change in expectations or projections, or any change in events,
conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither Kiadis nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the anticipated or
implied developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.
Sanofi
forward-looking
statementsThis press release
contains forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial
results, events, operations, services, product development and
potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words
“expects”, “anticipates”, “believes”, “intends”, “estimates”,
“plans” and similar expressions. Although Sanofi’s management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, risks related to Sanofi’s ability to complete the
acquisition on the proposed terms or on the proposed timeline, the
possibility that competing offers will be made, other risks
associated with executing business combination transactions, such
as the risk that the businesses will not be integrated
successfully, that such integration may be more difficult,
time-consuming or costly than expected or that the expected
benefits of the acquisition will not be realized, the uncertainties
inherent in research and development, future clinical data and
analysis, including post marketing, decisions by regulatory
authorities, such as the FDA or the EMA, regarding whether and when
to approve any drug, device or biological application that may be
filed for any such product candidates as well as their decisions
regarding labelling and other matters that could affect the
availability or commercial potential of such product candidates,
the fact that product candidates if approved may not be
commercially successful, the future approval and commercial success
of therapeutic alternatives, Sanofi’s ability to benefit from
external growth opportunities, to complete related transactions
and/or obtain regulatory clearances, risks associated with
intellectual property and any related pending or future litigation
and the ultimate outcome of such litigation, trends in exchange
rates and prevailing interest rates, volatile economic and market
conditions, cost containment initiatives and subsequent changes
thereto, and the impact that COVID-19 will have on us, our
customers, suppliers, vendors, and other business partners, and the
financial condition of any one of them, as well as on our employees
and on the global economy as a whole. Any material effect of
COVID-19 on any of the foregoing could also adversely impact us.
This situation is changing rapidly and additional impacts may arise
of which we are not currently aware and may exacerbate other
previously identified risks. The risks and uncertainties also
include the uncertainties discussed or identified in the public
filings with the SEC and the AMF made by Sanofi, including those
listed under “Risk Factors” and “Cautionary Statement Regarding
Forward-Looking Statements” in Sanofi’s annual report on Form 20-F
for the year ended December 31, 2020. Other than as required by
applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.